See Also
1. Diabetes Mellitus
Epidemiology
1. Represents 90% of all Diabetes Mellitus
2. Typically occurs over age 40 years in obese patients
Pathophysiology
1. Impairment of pancreatic beta-cell function
  1. Decreased beta cell response to glucose
    1. Abnormal Glucagon secretion
  2. Amyloidosis of islet cells (40% of patients)
  3. Pancreatic fibrosis (66% of patients)
    1. Associated fatty infiltration, vessel sclerosis
2. Decreased Insulin sensitivity (60-80% of patients)
  1. See Insulin Resistance
  2. Obesity
3. Course
  1. 12 years before diagnosis: Impaired Glucose Tolerance
    1. Insulin Resistance starts
    2. Insulin levels start to rise
    3. Fasting and post-meal glucose normal
  2. 8 years before diagnosis: Postprandial hyperglycemia
    1. Beta cell function at 75%
    2. Insulin levels increase to 150% of normal
    3. Fasting and post-meal glucose normal
  3. 2 years before diagnosis: Type 2 diabetes phase I
    1. Beta cell function at 50%
    2. Insulin levels increase to 200% of normal (peak)
    3. Post-prandial glucose 150-200 mg/dl
    4. Normal fasting glucose
  4. 2 years after diagnosis: Type 2 diabetes phase II
    1. Insulin levels fall to 150% of normal
    2. Post-prandial glucose 200 mg/dl
    3. Fasting glucose >140-150 mg/dl
  5. 8 years after diagnosis: Type 2 diabetes phase III
    1. Beta cell function at 25%
    2. Insulin levels fall to 100% of normal
  6. 14 years after diagnosis
    1. Beta cell function approaches 0%
    2. Insulin levels fall below 50% and approach 0
Etiology
1. Autosomal Recessive
Risk Factors:
1. Obesity (especially Apple Obesity)
2. Previous Gestational Diabetes (GDM)
3. Family History of Type II Diabetes Mellitus
4. Age over 40 years (risk increases with age)
  1. Type II Diabetes Mellitus does occur in children
5. Sedentary lifestyle (decreased Physical Activity)
6. Previously Impaired Glucose Tolerance (IGT)
7. Western diet
  1. Red meats and processed meats
  2. High fat foods (french fries, high fat dairy, eggs)
  3. High sugar foods, desserts and drinks
  4. Van Dam (2002) Ann Intern Med 136:201
8. Ethnicity
  1. Native American
  2. African American or Black
  3. Asian Type II Diabetics may be thin
  4. Hispanic
9. Cigarette smoking decreases Insulin sensitivity
  1. Targher (1997) Clin Endocrinol Metab 82:3619
Protective Factors (based on initial study findings)
1. See Insulin Resistance
Symptoms and Signs
1. See Diabetes Mellitus
Diagnostic Criteria
1. See Diabetes Mellitus
Associated Conditions
1. See Insulin Resistance
2. Acanthosis Nigricans
Labs
1. Urine Ketones: Usually negative
  1. Exception: Children with Type II Diabetes
2. See Diabetes Mellitus
Precautions: Accord Trial
1. Suggests higher risk of aggressively lowering Blood Glucose in Type II Diabetes
2. Risk increased with Hemoglobin A1C of 6.4% compared with 7.5%
3. Mortality was higher in the 6.4% A1C group by 3 per thousand patients
4. Endocrinologists still recommend goal of <7.0% and await larger trial (Advance)
5. References: NHLBI Questions and Answers regarding Accord Study
  1. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q_a.htm
Management: Summary
1. Medical nutrition therapy
  1. Indications to start at presentation
    1. Hemoglobin A1C <8%, Fasting BG <200, Random BG <250
  2. Efficacy: A1C decrease 1%
  3. Protocol
    1. Obese patients (Fasting glucose high)
      1. Insulin Resistance primary problem in early phase
      2. Focus on weight loss and activity
    2. Lean patients (Postprandial glucose high)
      1. Insulin deficiency is primary problem
      2. Focus on Carbohydrate Counting
2. Oral agents
  1. Indications to start at presentation
    1. Hemoglobin A1C 8-8.9%
    2. Fasting BG 200-250 mg/dl
    3. Random or casual BG 250-300 mg/dl
  2. Efficacy: A1C decrease 1-2% (combined with above)
  3. Protocol
    1. Obese patients (Fasting glucose high)
      1. Metformin (Glucophage)
      2. Glitazone (e.g. Pioglitazone, Rosiglitazone)
    2. Lean patients (Postprandial glucose high)
      1. Oral secretagogue (e.g. Sulfonylurea)
3. Combination therapy
  1. Indications to start at presentation
    1. Hemoglobin A1C 9-11%
    2. Fasting BG 251-300 mg/dl
    3. Random or casual BG 301-350 mg/dl
  2. Efficacy: A1C decrease 2-4% (combined with above)
  3. Protocol: Options
    1. Glucophage with Glitazone (esp. obese patients)
    2. Insulin Secretagogue with Glitazone
    3. Insulin Secretagogue with Glucophage
    4. Exenatide with Sulofnylurea
    5. Exenatide with Glucophage
4. Insulin Therapy
  1. Indications to start at presentation
    1. Hemoglobin A1C >11%
    2. Fasting BG >300 mg/dl
    3. Random or casual BG >350 mg/dl
  2. Protocol: Options
    1. Basal Insulin
    2. Basal with bolus Insulin
    3. Mixed Insulin
Management: General
1. Intensive Diabetic Education
  1. Goal Hemoglobin A1C <7.0
  2. Fasting plasma glucose: 70 to 140 mg/dl (ideal <105)
    1. New guidelines may suggest 70 to 120 mg/dl
  3. 2 hour postprandial glucose: <160 mg/dl (ideal <135)
    1. Ideally, only 20-40 mg/dl rise over pre-meal
  4. Bedtime glucose: 100-140 mg/dl
2. Weight loss if overweight
  1. Recommend 10-20 pound weight loss
  2. Lower caloric intake by 250-500 calories per day
3. Cardiovascular Disease Prevention
  1. Lower LDL Cholesterol <80-100 (Statin)
  2. Lower Blood Pressure <130/80 (ACE Inhibitor or ARB)
  3. Aspirin 81-160 mg PO qd
  4. ACE Inhibitor (Indicated in Proteinuria)
Management: Medications
1. First-line Oral Hypoglycemics
  1. See Oral Hypoglycemic agents
  2. Glucophage (Metformin) or
  3. Thiazolidinedione (if Glucophage contraindicated)
2. Insulin
  1. Indications
    1. Glucose toxicity
      1. Fasting Blood Glucose >250 mg/dl and
      2. Ketosis or weight loss
    2. Inadequate blood sugar control on oral agents
    3. Late stage Type II Diabetes (>5-10 years)
    4. Perioperative Diabetes Management
    5. Chronic Renal Failure
    6. Pregnancy
    7. Acute illness
  2. Protocol
    1. See Insulin Dosing
    2. Insulin augmentation with 0.15 units/kg daily
      1. NPH (Novolin N, Humulin N) qhs to bid
      2. Insulin Glargine (Lantus) daily
    3. Insulin replacement with 0.5 units/kg daily
      1. Long-acting basal Insulin (NPH or Lantus) and
      2. Short-acting bolus Insulin (Lispro, Aspart, Reg)
  3. Efficacy
    1. Insulin therapy does not reduce quality of life
    2. No increase in hypoglycemic episodes
    3. Significant improvement in glycemic control
    4. De Grauw (2001) Br J Gen Pract 51:527
Management: Initial
1. See Diabetes Mellitus Glucose Management
2. Sample Initial Protocol
  1. Fasting blood sugar <200 or random glucose <250
    1. Consider trial of diet and Exercise for 1-2 months
    2. Strongly consider concurrent Oral Hypoglycemic
  2. Fasting blood sugar <300 or random glucose <350
    1. Start Oral Hypoglycemic agent (see above)
  3. Fasting Blood Glucose >250 mg/dl and glucose toxicity
    1. Start Insulin replacement protocol (see above)
    2. Concurrently start Oral Hypoglycemic
  4. Fasting blood sugar >300 or random glucose >350
    1. Start Insulin replacement protocol (see above)
    2. Concurrently start Oral Hypoglycemic
Management: Follow-up Adjustment Phase
1. Weekly phone call to review Blood Glucose log
2. Monthly clinic visits
3. Dietician or nutritionist every 2-4 weeks
4. Goal Blood Glucose not met (Hemoglobin A1C >7.0)
  1. Oral Hypoglycemic agents not maximized
    1. Maximize dosing of current agents
    2. Add Sulfonylurea to Glucophage
    3. Add Thiazolidinedione if not already added
  2. Oral Hypoglycemics maximized or contraindicated
    1. Start Insulin augmentation (see above)
  3. Insulin augmentation has already been started
    1. Start Insulin replacement (see above)
Management: Follow-up Maintenance Phase
1. Clinic visits every 3-4 months
  1. Review Blood Sugar log and Hypoglycemic episodes
  2. Review medication dosages
  3. Evaluate comorbid conditions
    1. Evaluate weight or BMI
    2. Check Blood Pressure
  4. Clean and check Glucometer
2. Education
  1. Nutrition in Diabetes Mellitus
  2. Exercise in Diabetes Mellitus
  3. Foot Care (examine feet at every visit)
3. Examination
  1. Annual Health Maintenance Exam
  2. Annual Eye examination with Pupil Dilation
  3. Annual Dental Exam
4. Labs
  1. Daily
    1. Home glucose monitoring before meals and bedtime
    2. Postprandial Glucose (2 hours after meal)
      1. May be better marker for control
  2. Every 3 months
    1. Hemoglobin A1C
  3. Annual
    1. Fasting Lipid Profile
    2. Renal Function tests (BUN and Creatinine)
    3. Urinalysis
    4. Urine Microalbumin
References
1. Mayfield (2004) Am Fam Physician 70:489
2. Yki-Jarvinen (2001) 24:758

Diabetes Mellitus, Non-Insulin-Dependent (C0011860)
Definition (CSP)	subclass of diabetes mellitus that is not insulin responsive or dependent; characterized initially by insulin resistance and hyperinsulinemia and eventually by glucose intolerance, hyperglycemia, and overt diabetes; type II diabetes mellitus is no longer considered a disease exclusively found in adults; patients seldom develop ketosis but often exhibit obesity.
Definition (MSH)	A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Concepts	Disease or Syndrome (T047)
English	ADULT ONSET DIABETES MELLITUS, AODM, DIABETES MELLITUS TYPE 02, Diabetes mellitus type 2, Diabetes mellitus type II, ketosis resistant diabetes, Maturity onset diabetes, Maturity onset diabetes mellitus, MOD, MODY, NCDMM, NIDDM, Noninsulin dependent diab.mell, noninsulin dependent diabetes mellitus, Stable Diabetes Mellitus, type 2 diabetes, Type 2 Diabetes Mellitus, Type II Diabetes, type II diabetes mellitus
Spanish	diabetes mellitus no dependiente de insulina, diabetes mellitus tipo II
Credits	Derived from the NIH UMLS (Unified Medical Language System)

Navigation Tree

Please see the Terms and Conditions. Please also see the privacy statement regarding advertising on this page. Although access to this page is not restricted, the information found here is intended for use by medical providers. Patients should address specific medical concerns with their physicians.

This page was written by Scott Moses, MD. This page was last revised before 5/10/08, prior to consistent tracking of revision date. This page was last published on 5/10/2008. Please send comments and questions to the editor. Contact information may be found on the page About the Family Practice Notebook. These pages are best viewed with Microsoft Internet Explorer 6.0.

Endocrinology Book

Approach

Disease Complications

Information Resources

Management

Dermatology Chapter related topics

Examination Chapter related topics

Nephrology Chapter related topics

Neurology Chapter related topics

Obstetrics Chapter related topics

Ophthalmology Chapter related topics

Pathology and Laboratory Medicine Chapter related topics

Pharmacology Chapter related topics

Prevention Chapter related topics

Sports Medicine Chapter related topics

Surgery Chapter related topics

http://www.fpnotebook.com/

Type 2 Diabetes MellitusAka: Type II Diabetes Mellitus, Non-Insulin Dependent Diabetes Mellitus, NIDDM, Type II Diabetes

Diabetes Mellitus, Non-Insulin-Dependent (C0011860)

Navigation Tree